



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbsilpa.com, Web: www.vbsilpa.com
CIN: L85110KA1987PLC008739

Dated: 21 Jan, 2022

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa's Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to Use formulation is approved by European Authorities

This is to inform you that **Shilpa's Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to use formulation is approved by European Authorities**, through its agreed partners in Europe. The product will be manufactured, for EU commercialization at its own EU GMP compliant, injectable manufacturing facility situated in Telangana state.

Shilpa has developed Pemetrexed formulation as liquid/ ready to use injection, against lyophilized powder formulation of reference, ALIMTA®.

Shilpa's Pemetrexed Injection is a unique formulation, which is supplied as ready to use formulation without any further dilution. The product is stable at room temperature.

Pemetrexed injection is used in the treatment of malignant pleural mesothelioma & non-small cell lung cancer.

According to IQVIA MAT Q2'2021 (June 2021) data, the EU market for **Pemetrexed Injection** is approximately EURO 519 Million.

With Regards,

For **SHILPA MEDICARE LIMITED**

V V Krishna Chaitanya

Company Secretary & Compliance Officer